ProtoKinetix recorded recurring operating losses of $393,650 for the year ended December 31, 2025 and said it needs increased Research and Development funding. The company’s outlook matters because management expects additional funds will likely be required to pursue product development, while identified risks include limited operating history, no Operating Revenue and financing difficulty.

Key Highlights

  • ProtoKinetix spent $106,613 on research and development during 2025.
  • Professional fees reached $177,610, while general and administrative expenses were $58,135.
  • Management identified regulatory approval, market acceptance and additional-capital risks for future products.

For 2025, ProtoKinetix, Inc. (OTC: PKTX) recorded recurring operating losses of $393,650. The research and development-stage biotechnology company said it needs to increase funding for research activities and will likely require additional funds. ProtoKinetix reported no operating revenues and said its ability to advance development depends on raising money.

$393,650 Operating Loss

The company’s net loss for 2025 was $393,650, compared with $364,188 for 2024. Operating expenses included $177,610 in professional fees, $106,613 in research and development, $58,135 in general and administrative costs and $51,292 in amortization. Research and development expenses were $106,613 in 2025, compared with $99,625 in 2024. Amortization was $51,292, down from $52,870, while general and administrative expenses fell to $58,135 from $61,470. Professional fees rose to $177,610 from $144,807. The company also reported negative net Operating Cash Flow of $135,377 for 2025, compared with $223,050 for 2024. ProtoKinetix said it has never paid cash dividends.

Research Spending And AAGP Testing

ProtoKinetix said higher research and development spending in 2025 reflected increased storage fees for molecule inventory. The company has scaled back new research while seeking to build on positive study findings. ProtoKinetix said ongoing AAGP testing indicates potential for protecting cells, tissue and organs against various stresses. The company said future projects will involve targeted investments in expanding AAGP molecule development through institutional collaborations and industry partnerships. It is also working to improve the Manufacturing process, reduce costs and increase purity and biochemical activity. ProtoKinetix said it is pursuing industry partners to move its research forward. The filing says no product has yet been developed or marketed.

Additional Funding Required

ProtoKinetix said increased research and development funding will be necessary to reach its goal of developing a marketable product. The company’s ability to raise money currently limits that work. The filing says ProtoKinetix will likely need additional funds for research and development, non-clinical and clinical trials, clinical and commercial-scale manufacturing arrangements, Marketing and distribution. It warns that insufficient funding could lead to delays, reduced scope or elimination of related efforts. The company’s independent public accountants noted that recurring operating losses of $393,650 and negative net operating cash flow of $135,377 raised substantial doubt about its ability to continue as a going concern. ProtoKinetix said that situation may hinder its ability to obtain financing or require financing on less favorable terms.

Ownership And Operating Risks

ProtoKinetix identified a lack of operating history and operating revenue as principal risks. The company also said it has a limited operating history, has not developed or sold products and may have difficulty raising needed capital. Regulatory approval and market acceptance present further risks. The filing says directors and executive officers currently have voting rights over approximately 7.83% of outstanding voting stock. ProtoKinetix said this concentration may allow these holders, acting together, to exert significant control over company decisions and matters submitted to stockholders.